Literature DB >> 23132698

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly.

Johan Verhelst1, Brigitte Velkeniers, Dominique Maiter, Patrick Haentjens, Guy T'Sjoen, Ernst Rietzschel, Bernard Corvilain, Pascale Abrams, Frank Nobels, Roger Abs, Marie Bex.   

Abstract

OBJECTIVE: Patients with active acromegaly have an increased prevalence of cardiomyopathy and heart failure but a less than expected risk of coronary artery disease, considering the frequent association of diabetes mellitus and hypertension. We examined whether changes in high-sensitive C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) might contribute to this phenomenon. DESIGN AND METHODS: Two hundred patients of the Belgian acromegaly registry (AcroBel) were divided in two groups: active disease (IGF1 Z-score >2; n=95) and controlled disease (IGF1 Z-score ≤2; n=105). Serum levels of hs-CRP and NT-proBNP were measured and correlated with BMI, blood pressure, fasting lipids, fasting glucose and insulin, HbA1c, IGF1, interleukin 6 (IL6), adiponectin, and sE-selectin. In a subset of acromegaly patients, hs-CRP, IL6, and NT-proBNP levels were also compared with those/the values of an age-, gender-, and BMI-matched reference group.
RESULTS: Patients with active acromegaly had significantly lower levels of hs-CRP (median (interquartile range), 0.5 mg/l (0.1, 0.9) vs 1.3 mg/l (0.5, 4.1); P<0.001) and NT-proBNP, (47.0 ng/l (26.0, 86.0) vs 71.0 ng/l (43.0, 184.0); P<0.001) compared with patients with controlled acromegaly. Compared with the reference population, hs-CRP was not different in controlled acromegaly but significantly lower in active acromegaly (median, 0.4 mg/l (0.1, 0.8) vs 1.4 mg/l (0.8, 2.9); P<0.001), while NT-proBNP was similar in active acromegaly but significantly higher in controlled acromegaly (66.5 ng/l (40.0, 119.5) vs 50.8 ng/l (26.5, 79.7); P<0.001).
CONCLUSIONS: Patients with active acromegaly have significantly lower values of NT-proBNP and hs-CRP compared with patients with controlled disease and even lower values of hs-CRP compared with control subjects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23132698     DOI: 10.1530/EJE-12-0753

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.

Authors:  Cigdem Ozkan; Alev Eroglu Altinova; Ethem Turgay Cerit; Cagri Yayla; Asife Sahinarslan; Duygu Sahin; Aylin Sepici Dincel; Fusun Balos Toruner; Mujde Akturk; Metin Arslan
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

3.  High chitotriosidase and AGE levels in acromegaly: a case-control study.

Authors:  Hatice Ozisik; Banu Sarer Yurekli; Aslı Suner; Oznur Copur; Eser Yıldırım Sozmen; Suha Sureyya Ozbek; Ahmet Kasım Karabulut; Ilgın Yıldırım Simsir; Mehmet Erdogan; Sevki Cetinkalp; Fusun Saygili
Journal:  Hormones (Athens)       Date:  2022-10-15       Impact factor: 3.419

4.  Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untreated, congenital isolated GH deficiency.

Authors:  Cindi G Marinho; Hyder A Melo; Roberto Salvatori; Marco A P Nunes; Carla R P Oliveira; Viviane C Campos; Cynthia S Barros-Oliveira; Alécia A Oliveira-Santos; Nelmo V Menezes; Hertz T Santos-Júnior; Elenilde G Santos; Manuela A Melo; Joselina L M Oliveira; Enaldo V Melo; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

Review 5.  A Functional Interplay between IGF-1 and Adiponectin.

Authors:  Stefania Orrù; Ersilia Nigro; Annalisa Mandola; Andreina Alfieri; Pasqualina Buono; Aurora Daniele; Annamaria Mancini; Esther Imperlini
Journal:  Int J Mol Sci       Date:  2017-10-14       Impact factor: 5.923

6.  Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study.

Authors:  Xiaopeng Guo; Kailu Wang; Siyue Yu; Lu Gao; Zihao Wang; Huijuan Zhu; Bing Xing; Shuyang Zhang; Dong Dong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-01       Impact factor: 5.555

Review 7.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

8.  Quantitative measures of the vascular and neural components of the retina in adult individuals with congenital and untreated growth hormone deficiency.

Authors:  Nelmo V Menezes; Cynthia S Barros-Oliveira; Roberto Salvatori; Vinicius C Gois; Cindi G Marinho; Carla R P Oliveira; Viviane C Campos; Alécia A Oliveira-Santos; Hertz T Santos-Júnior; Elenilde G Santos; Enaldo V Melo; Augusto C N Faro; Neima V Oliveira; Hérika M Gumes-Felix; Gustavo B Melo; Manuel H Aguiar-Oliveira
Journal:  Int J Retina Vitreous       Date:  2022-10-01

Review 9.  GH and the cardiovascular system: an update on a topic at heart.

Authors:  Jörgen Isgaard; Michele Arcopinto; Kristjan Karason; Antonio Cittadini
Journal:  Endocrine       Date:  2014-06-28       Impact factor: 3.633

10.  Serum NT-pro-BNP Levels Predict Cardiovascular Events in Acromegaly Patients.

Authors:  Marta Ragonese; Gianluca Di Bella; Federica Spagnolo; Loredana Grasso; Angela Alibrandi; Guiseppe Giuffrida; Mariacarla Moleti; Francesco Ferraù; Salvatore Cannavò
Journal:  Exp Clin Endocrinol Diabetes       Date:  2021-12-23       Impact factor: 2.426

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.